- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-2965
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Denosumab and muscle performance ; volume:34 ; number:1 ; day:15 ; month:11 ; year:2022 ; pages:211-212 ; date:1.2023
Osteoporosis international ; 34, Heft 1 (15.11.2022), 211-212, 1.2023
- Urheber
-
Rolvien, Tim
Rupp, Tobias
Strahl, André
Amling, Michael
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00198-022-06587-5
- URN
-
urn:nbn:de:101:1-2023031321142250813153
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rolvien, Tim
- Rupp, Tobias
- Strahl, André
- Amling, Michael
- SpringerLink (Online service)
Ähnliche Objekte (12)
Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study
Denosumab: A comprehensive review
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
Sialylation and muscle performance: sialic Acid is a marker of muscle ageing
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
Denosumab-assoziierte Kiefernekrosen : klinische Präsentation und potenzielle Risikofaktoren
Observations following discontinuation of long-term denosumab therapy
Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course
Denosumab : RANKL-Inhibition zur Therapie metabolischer und maligner Osteopathien
Histologische und immunhistochemische Untersuchungen an Kieferosteonekrosen unter Denosumab-Therapie
Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study
Denosumab: A comprehensive review
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
Sialylation and muscle performance: sialic Acid is a marker of muscle ageing
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
Denosumab-assoziierte Kiefernekrosen : klinische Präsentation und potenzielle Risikofaktoren
Observations following discontinuation of long-term denosumab therapy
Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course
Denosumab : RANKL-Inhibition zur Therapie metabolischer und maligner Osteopathien
Histologische und immunhistochemische Untersuchungen an Kieferosteonekrosen unter Denosumab-Therapie
Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study
Denosumab: A comprehensive review
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
Sialylation and muscle performance: sialic Acid is a marker of muscle ageing
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
Denosumab-assoziierte Kiefernekrosen : klinische Präsentation und potenzielle Risikofaktoren
Observations following discontinuation of long-term denosumab therapy
Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism
Medication-related osteonecrosis of the jaw : bisphosphonates, denosumab, and new agents
Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course
Denosumab : RANKL-Inhibition zur Therapie metabolischer und maligner Osteopathien